Pediatrics

The drug will be available in pharmacies during the second half of 2024.

Altuviiio was first granted approval by the FDA in February 2023.

Check out this list of resources to share with patients who are managing an allergy or asthma diagnosis.

Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.

A study from the Children’s Hospital of Philadelphia found that a positive PCR test was not associated with an increased risk of a new asthma diagnosis in patients ages 1 to 16.

Fasenra was initially approved in 2017 as an add on maintenance therapy in patients aged 12 years and older.

Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.

Rilpivirine (Edurant Ped) effectively suppresses the HIV-1 virus in pediatric patients with HIV-1 RNA less than or equal to 100,000 copies/mL in combination with other antiretroviral therapies.

Medical spending on pediatric mental health conditions accounted for 46.6% of all pediatric medical spending in 2021.

Despite previously suggested benchmarks, investigators found that spending less time-in-range (TIR) can still improve maternal and perinatal outcomes among pregnant patients with type 1 diabetes (T1D).

As a result of an increase in adolescent inpatient visits with a sexually transmitted infection (STI) diagnosis in 2020, further work is needed to improve STI care, particularly for this demographic.

The FDA states the revision to the emergency use authorization (EUA) is the next phase in the transition from the use of EUA-labeled nirmatrelvir and ritonavir to the use of NDA-labeled nirmatrelvir and ritonavir.

Although the risk of respiratory distress among infants exposed to SARS-CoV-2 is high, the odds of developing the condition decreased by 67% among neonates born to vaccinated mothers.

Although the study identified an increase in chronic symptoms among children that developed post-COVID-19 condition, the chance of initial development was low.

Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

An FDA-approval of Omalizumab would help reduce allergic reactions among 17 million people in the United States who have confirmed food allergies.

Tralokinumab is the first form of atopic dermatitis treatment that targets the interleukin-13 cytokine, the main source of atopic dermatitis symptoms.

Immunizations against influenza, COVID-19, and RSV are lower than they were this time last year, and hospitalizations have increased across all age groups.

According to a poster presented at ASHP Midyear 2023, stress ulcer prophylaxis (SUP) did not increase adverse effects, suggesting limited preventive benefits for gastrointestinal bleeding (GIB) in neonates.

The FDA is advising health care professionals who administer the vaccine to make sure the correct volume of the vaccine is withdrawn from the vial and the correct dose is administered to the patient.

A poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition, featured a complex pediatric case involving SARS-CoV-2, bacterial coinfection, multiorgan failure, thrombotic microangiopathy, and systemic hyperinflammation.